Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5860922 | 0.93 | MCHR1 (0.49) | MCHR1MEN1KMT2ACASP3SENP8 | |
| SCHEMBL5862119 | 0.87 | MCHR1 (0.71) | MCHR1 | |
| SCHEMBL5862808 | 0.85 | MCHR1 (0.54) | MCHR1NPC1RAB9A | |
| SCHEMBL5860794 | 0.83 | MCHR1 (0.60) | MCHR1NPC1RAB9A | |
| SCHEMBL5861236 | 0.82 | MCHR1 (0.48) | MCHR1IRAK4NPC1RAB9A | |
| SCHEMBL6194177 | 0.81 | NPC1 (0.51) | MCHR1MEN1KMT2AIRAK4NPC1 | |
| SCHEMBL5862841 | 0.79 | MCHR1 (0.60) | MCHR1 | |
| SCHEMBL5860873 | 0.78 | MCHR1 (0.54) | MCHR1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5861972 | 0.78 | MCHR1 (0.67) | MCHR1 | |
| SCHEMBL5862884 | 0.76 | MCHR1 (0.65) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7049307-B2 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES (US) | 2006-05-23 | — | — | US | claimed |
| US-20050187279-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBVIE INC. | 2005-08-25 | — | — | US | claimed |
| US-20050137187-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | claimed |
| US-7049307-B2 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES (US) | 2006-05-23 | — | — | US | disclosed |
| US-20050187279-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBVIE INC. | 2005-08-25 | — | — | US | disclosed |
| US-20050137187-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137187-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | MCHR1 1/4885MEN1 204/4885KMT2A 1558/4885 |
| US-20050187279-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | MCHR1 1/4885MEN1 204/4885KMT2A 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.